Our unparalleded technology platform led to the discovery
and validation of an unprecedented product pipeline for the early detection
of major cancers and their monitoring
Milagen is a privately held innovative In Vitro Diagnostic (IVD) company founded in 1997 with the goal of developing biomarkers and immunoassays for the diagnosis and management of major cancers.
The company product portfolio features a new generation of IVD assays designed to fulfill unmet clinical needs in cancer diagnostics, with potential impact on early detection.
While the rest of the industry was focusing on gene-based biomarker discovery, Milagen developed a distinct innovative antibody-based proteomic approach.
Using its proprietary technologies, Milagen applied a collection of antibody reagents to the screening of a variety of clinical samples (tissue, serum/plasma and urine) leading to the discovery of novel candidate cancer biomarkers.
Based on a portfolio of secreted proprietary cancer biomarkers, Milagen has developed novel IVD products, in the form of non-invasive immunodiagnostic assays, for cancer surveillance and detection, including at early stage.
In addition to novel proprietary cancer IVD assays, Milagen offers a portfolio of immunohistochemistry (IHC) reagents which are used in IVD laboratories to support cancer diagnosis.
Finally, Milagen has developed the Multiwell Liquid-Based Cytology System, a novel fully integrated platform designed for high throughput affordable manual cytology evaluation and cervical disease screening.